What smart money is saying about Oxford Biomedica
OXB.L
No fund has written a full thesis on Oxford Biomedica in our archive, but 4 fund letters report a position in it — most recently Liontrust Sustainable Future UK Growth Fund in September 2026.
Get an email when a fund buys, sells or pitches it
4
Reported positions
0
Bought
4
Sold
4
Letters
Position history
Every position in Oxford Biomedica on record in the archive was reported in Q3 2026, across 4 fund letters — 4 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 4 | 0 |
Fund activity · 4 positions · 4 moves
- September 2026
“We exited the stock, but continue to watch the company closely to gain conviction in its offering and its handling of its pipeline.”
Oxford Biomedica - September 2026
“Oxford Biomedica is a leader in cell and gene therapy innovation and manufacturing, was also sold over the period. In mid-2026, a large guidance downgrade coupled with negative news flow on pharmaceutical companies pausing or halting their cutting edge CAR-T gene therapy trials gave us pause for thought. OXB remains highly exposed to the riskier, bumpier end of medicine in early-stage trials in cell and gene therapy and due to its size, is overexposed to delays in its pipeline. We exited the stock, but continue to watch the company closely to gain conviction in its offering and its handling of its pipeline.”
Oxford Biomedica - September 2026
“Oxford Biomedica is a leader in cell and gene therapy innovation and manufacturing, was also sold over the period. In mid-2026, a large guidance downgrade coupled with negative news flow on pharmaceutical companies pausing or halting their cutting edge CAR-T gene therapy trials gave us pause for thought. OXB remains highly exposed to the riskier, bumpier end of medicine in early-stage trials in cell and gene therapy and due to its size, is overexposed to delays in its pipeline. We exited the stock, but continue to watch the company closely to gain conviction in its offering and its handling of its pipeline.”
Oxford Biomedica - September 2026
“Oxford Biomedica is a leader in cell and gene therapy innovation and manufacturing, was also sold over the period. In mid-2026, a large guidance downgrade coupled with negative news flow on pharmaceutical companies pausing or halting their cutting edge CAR-T gene therapy trials gave us pause for thought. OXB remains highly exposed to the riskier, bumpier end of medicine in early-stage trials in cell and gene therapy and due to its size, is overexposed to delays in its pipeline. We exited the stock, but continue to watch the company closely to gain conviction in its offering and its handling of its pipeline.”
Oxford Biomedica
Read the letters behind these Oxford Biomedica positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger